INDEPENDENT VERDICT
Ellipsys Medical, Inc. is a newly formed Delaware medical-device company whose 2026 financing is tied to an unusually mature underlying product. The September 17 Form D amendment reports a fixed $10.85 million Equity offering under Rule 506(b), with $5,906,665 sold to 39 investors and $4,943,335 remaining after first sale on August 22. That represents a significant increase from the initial September 8 notice, which reported $3,771,795 sold to 28 investors. The issuer is classified as Other Health Care rather than a pooled investment fund, reports no sales commissions or finder fees, declines to disclose revenue range and lists Frank Hettmann as executive officer and director alongside directors Ed Chang, Mark Ritchart, Steve Parker, Jeffrey Hull and Brian Driscoll. The most important point, however, is that these investors are not financing the first attempt to prove Ellipsys works; they are financing the return of a device whose regulatory and corporate history reaches back almost a decade.
The Ellipsys Vascular Access System was originally developed by Avenu Medical as a minimally invasive alternative to surgically creating an arteriovenous fistula for hemodialysis patients. FDA granted the system De Novo authorization in June 2018, creating a new device classification for percutaneous catheter-based AV-fistula creation. FDA's review included a multicenter study of 103 patients in which 92 patients, or 89.3%, met the agency's usable-fistula criteria within three months, although the agency also noted that 96.1% required an additional procedure during the first 12 months to maintain the fistula. The clinical story is therefore more nuanced than a simple "non-surgical replacement": Ellipsys demonstrated that fistulas could be created percutaneously with a single catheter and ultrasound guidance, but post-creation maturation and maintenance remained an important part of the care pathway.
ACQUIRED BY MEDTRONIC, DISCONTINUED, THEN BOUGHT BACK INTO INDEPENDENCE
The corporate history is what makes the 2026 Form D unusually distinctive. Medtronic announced its acquisition of Avenu Medical in September 2020, specifically citing the Ellipsys system as an addition to its peripheral vascular-access portfolio for end-stage renal disease patients. At the time, Medtronic highlighted the system's single-catheter, ultrasound-guided approach and viewed dialysis vascular access as a meaningful strategic market; its investor materials described a large U.S. vascular-access opportunity and cited durable Ellipsys performance data. (news.medtronic.com)
But large-company ownership did not permanently secure the product's future. Medtronic later discontinued Ellipsys commercialization in 2025 while refocusing its portfolio and exiting the fistula-creation market. Rather than allowing the system to disappear, Medtronic ultimately agreed to sell the Ellipsys Vascular Access System to a new company, Ellipsys Medical Inc., founded by leaders with deep experience in the field. Medtronic itself told Endovascular Today that it had explored alternatives after discontinuation and was pleased the new company would continue providing the minimally invasive AV-fistula technology. This reversal creates an uncommon medtech investment setup: the new issuer is effectively rebuilding an independent commercial organization around an asset that has already passed FDA review, survived acquisition by a global strategic buyer and then been divested after a portfolio-level decision.
The personnel continuity strengthens that interpretation. Ed Chang is publicly identified as a co-founder, director and former CMO of Avenu Medical, while Jeffrey Hull was also a co-founder of Avenu and a physician closely involved with Ellipsys development. Both names now appear on the new Ellipsys Medical Form D board. Frank Hettmann leads the new company as president, and the current board also includes Mark Ritchart, Steve Parker and Brian Driscoll. That does not mean the new company is legally the same entity as Avenu or Medtronic; it is a new Delaware corporation formed in 2026. It does show that the commercial restart is being driven by people with direct historical connection to the technology rather than by an unrelated financial buyer.
THE FDA RECORD SHOWS A TRUE PRODUCT TRANSFER, NOT JUST A BRAND RELAUNCH
The regulatory trail provides unusually strong independent confirmation that the technology has actually moved into the new organization. FDA's GUDID database now lists an active Ellipsys device under Ellipsys, Inc., with model AMI-6005 and status "In Commercial Distribution." The new device record was published in June 2026, identifies the Ellipsys catheter and power controller, provides an Ellipsys Medical customer-support email, and explicitly records a previous device identifier associated with the earlier product lineage. This is important because it links the new company's public identity to an active regulated device record rather than relying only on branding or social media.
At the same time, the legacy FDA record remains traceable to Avenu Medical. The original De Novo authorization names Avenu as requester, and subsequent 510(k) records also identify Avenu as the applicant. The newer GUDID registration therefore shows regulatory continuity across a change in commercial owner: Avenu developed and cleared the system, Medtronic acquired the developer, and the current Ellipsys entity now appears as the label company for the commercially distributed product. That chain is materially stronger evidence than simply finding an old FDA clearance with the same product name.
Ellipsys Medical has also publicly stated that the system has returned to market and announced the first new commercial cases performed at STAR Vascular Access Center and Azura Vascular Care Jacksonville. Those cases matter because a relaunch requires more than transferring intellectual property: the company must rebuild manufacturing, sterile supply, quality systems, physician training, field support, reimbursement workflows and clinical inventory. The current LinkedIn profile places the company at the same 990 Calle Negocio address shown in the SEC filing and describes a small 11-50-person privately held medical-device team founded in 2025/2026 around the Ellipsys system.
THE SEC AMENDMENT SHOWS CAPITAL ARRIVING WHILE COMMERCIALIZATION RESTARTS
The financing timeline deserves more attention than the static $10.85 million target. The initial filing reported $3.771795 million sold to 28 investors; the September 17 amendment increased the sold amount to $5.906665 million and investor count to 39 without changing the $10.85 million ceiling. In roughly nine days, Ellipsys therefore added about $2.135 million of reported equity sales and 11 investors. That does not prove the company will complete the remaining $4.943 million, but it provides a rare near-real-time indication that the offering continued to attract capital after the initial notice.
This capital is arriving exactly when the operating burden is likely to be highest. Unlike a software relaunch, a Class II medical-device business requires controlled manufacturing, quality systems, supplier qualification, complaint handling, regulatory maintenance and field inventory. The Ellipsys catheter is single-use while the power controller is reusable, creating a business model that potentially combines installed equipment with recurring disposable consumption. But investors need actual economics: manufacturing cost per catheter, controller placement strategy, average selling price, hospital or outpatient reimbursement, gross margin, physician training cost, annual procedure volume and working-capital requirements are not disclosed in Form D. The filing also reports $0 Item 16 payments to listed insiders, meaning no proceeds are disclosed there as planned related-person payments, but that does not reveal the overall operating budget or salaries.
A RELAUNCH HAS LOWER TECHNOLOGY RISK BUT HIGHER COMMERCIAL-EXECUTION RISK
The investment thesis is fundamentally different from backing a pre-clearance medtech startup. Ellipsys does not have to prove from scratch that FDA will permit marketing of a catheter-based AV-fistula system; the device already created its own De Novo classification and has a long regulatory history. Nor does the market need to be educated from zero that percutaneous AV-fistula creation is technically possible. The risk has shifted toward restoring adoption, physician confidence and commercial infrastructure after a period in which Medtronic stopped selling the device.
That history also creates a difficult but important diligence question: why did a company as large as Medtronic decide not to continue commercializing Ellipsys Public reporting characterizes the decision as part of portfolio refocusing and Medtronic's exit from fistula creation, not as an FDA withdrawal or proof that the device failed. Still, investors should examine actual procedure volumes, sales history under Medtronic, customer retention, reimbursement economics, competing endoAVF systems, service burden and whether adoption was constrained by clinical workflow rather than corporate strategy alone. A product can be clinically valid yet commercially difficult, especially when it changes referral patterns or requires specialized ultrasound skills.
The original FDA data also reinforces the need for nuance. The system achieved a high rate of usable AV fistulas within three months, but many patients required subsequent procedures. Investors should therefore avoid marketing the product as eliminating follow-up interventions. The relevant commercial question is whether the total patient experience, procedure setting, time, complication profile and lifetime access economics are sufficiently attractive for physicians, dialysis providers and payers to drive sustained adoption. FDA authorization verifies a regulatory threshold, not market dominance.
FINAL ASSESSMENT
Ellipsys Medical's 2026 Form D is much more than a conventional early-stage medtech financing. The new company is raising up to $10.85 million after reacquiring a device lineage that began at Avenu Medical, received FDA De Novo authorization in 2018, was acquired by Medtronic in 2020, was later discontinued by Medtronic and has now returned to independent commercial distribution. FDA's current device database independently identifies Ellipsys, Inc. as the company behind a commercially distributed AMI-6005 Ellipsys device, while the new company has publicly announced resumed commercial procedures.
The financing trajectory provides a second distinctive signal. Reported sales increased from $3.77 million and 28 investors in the initial Form D to $5.91 million and 39 investors in the amendment, leaving about $4.94 million still available under the $10.85 million target. The capital is therefore being assembled while the company is actively restoring product supply and physician use rather than years before commercialization.
The strongest independent conclusion is that Ellipsys investors are underwriting a commercial resurrection, not a scientific invention. Regulatory validity and historical clinical evidence already exist; what must now be proven is whether a focused independent company can do what Medtronic ultimately chose not to continue doing—manufacture the product efficiently, rebuild the physician network, secure durable reimbursement and create a profitable recurring business around dialysis vascular access. Investors should request the Medtronic asset-purchase terms, transferred IP schedule, current FDA responsibility matrix, historical and post-relaunch procedure volume, unit economics, customer pipeline, competing-product data and cash runway before treating the device's prior strategic ownership as evidence that the new company will succeed commercially.
Form D is an exempt-offering notice. It is not SEC approval of Ellipsys Medical, the Ellipsys Vascular Access System, its FDA status, the Medtronic divestiture or any investment return.
SEC SNAPSHOT
ISSUER: Ellipsys Medical, Inc. | PREVIOUS NAME: Ellipsys, Inc. | CIK: 0002153524 | SEC FILE NO.: 021-596570 | INITIAL FORM D FILED: September 8, 2026 | LATEST AMENDMENT: September 17, 2026
ENTITY: Delaware Corporation | FORMED: 2026 | PRINCIPAL ADDRESS: 990 Calle Negocio, San Clemente, CA 92673 | PHONE: 949-485-1155
INDUSTRY: Other Health Care | EXEMPTION: Regulation D Rule 506(b) | POOLED FUND: No | SECURITY: Equity | BUSINESS COMBINATION: No
FIRST SALE: August 22, 2026 | OFFERING DURATION: One year or less | TOTAL OFFERING: $10,850,000
INITIAL SEPTEMBER 8 STATUS: $3,771,795 sold | $7,078,205 remaining | 28 investors.
LATEST SEPTEMBER 17 STATUS: $5,906,665 sold | $4,943,335 remaining | 39 investors.
INCREASE BETWEEN FILINGS: approximately $2,134,870 additional amount sold | 11 additional reported investors.
SALES COMMISSIONS: $0 | FINDER FEES: $0 | ITEM 16 RELATED-PERSON PAYMENTS: $0 | REVENUE RANGE: Declined to disclose.
RELATED PERSONS: Frank Hettmann — Executive Officer / Director / President | Ed Chang — Director | Mark Ritchart — Director | Steve Parker — Director | Jeffrey Hull — Director | Brian Driscoll — Director.
PRIMARY PRODUCT: Ellipsys Vascular Access System | PURPOSE: Percutaneous creation of an arteriovenous fistula for hemodialysis access using a single-catheter, ultrasound-guided approach.
ORIGINAL FDA PATHWAY: De Novo DEN170004 | GRANTED: June 22, 2018 | ORIGINAL REQUESTER: Avenu Medical, Inc.
FDA CLINICAL EVIDENCE AT DE NOVO REVIEW: 103-patient multicenter study | 89.3% met usable-fistula criteria within three months | FDA reported 96.1% required an additional procedure during the first 12 months to maintain the fistula.
OWNERSHIP HISTORY: Avenu Medical developed Ellipsys | Medtronic announced acquisition of Avenu in 2020 | Medtronic later discontinued Ellipsys commercialization in 2025 as it exited fistula creation | Medtronic subsequently agreed to sell the Ellipsys system to newly formed Ellipsys Medical Inc.
CURRENT FDA / GUDID STATUS: Ellipsys Medical-branded AMI-6005 record lists Ellipsys, Inc. as company | commercial distribution status: In Commercial Distribution | new GUDID record published June 2026.
COMMERCIAL RELAUNCH: Ellipsys Medical publicly announced that the system had returned to market and that initial new commercial cases had been completed at U.S. vascular-access centers.
IMPORTANT ENTITY DISTINCTION: Ellipsys Medical Inc. is a new 2026 company. It is not the original Avenu Medical corporation and should not automatically inherit Avenu or Medtronic revenue, assets or historical valuation.
IMPORTANT REGULATORY DISTINCTION: The product's FDA De Novo authorization predates the new company. The current GUDID record supports transfer into the new commercial organization, but FDA authorization is not an endorsement of the company's financing or future financial performance.
CORE INDEPENDENT FINDING: Ellipsys Medical's financing is a rare "second-life medtech" transaction. Investors are funding the revival of an FDA-authorized dialysis-access technology that was previously acquired by Medtronic and then discontinued, with the original product ecosystem now being rebuilt under a small independent company. The central risk has therefore moved away from basic regulatory invention and toward manufacturing restart, reimbursement, clinical adoption, procedure economics and whether focused ownership can make a product commercially successful after a major strategic owner chose to leave the category.
Form D is an exempt-offering notice and is not an SEC-issued certificate, approval or endorsement.